3-substituted quinuclidines and their use as nicotinic agonists
This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
1. A 3-substituted quinuclidine compound represented by Formula I
wherein
- - - - represents an optional double bond; and
R′ represents a bicyclic carbocyclic group
which bicyclic carbocyclic group is optionally substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkoxy, alkoxycycloalkyl, cycloalkoxyalkoxy, cycloalkylalkyl, hydroxyalkoxy, alkenyl, alkoxyalkenyl, alkynyl, alkoxyalkynyl, alkenoxy, alkynoxy, alkylthio, alkenylthio, alkynylthio, alkylseleno, alkenylseleno, alkynylseleno, methylenedioxy, trifluoromethanesulfonyloxy, halogen, —OH, —CF 3 , —OCF 3 , —CN, amino, nitro, oxime, alkyloxime, acyloxime, a group of the formula —(CO)R 3 , —COOR 3 , —O(CO)R 3 , —CONR 2 R 3 , —NH—CO 2 R 2 , —NHCO—R 2 and —OCO—NR 2 R 3 ; in which formulas R 2 and R 3 independently of each another represents hydrogen or alkyl;
any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
2. The quinuclidine compound of claim 1 , wherein the bicyclic carbocyclic group is indenyl or naphthyl.
3. The quinuclidine compound of claim 2 , which is
3-(2-Naphthyl)-quinuclidine-3-ene; or
(±)-3-(2-Naphthyl)-quinuclidine;
any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a therapeutically effective amount of a 3-substituted quinuclidine compound of claim 1 , any of its enantiomers or any mixture of enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier or diluent.